In a small subpopulation of people living with T1D, transplantation of beta cells can be, literally, a life-saver. Unfortunately, they require long-term immunosuppressive treatments, and most of those beta cells will be gone at two years, rendering these people insulin-dependent again. One avenue to overcome this is to produce the beta cells from stem cells, which have been modified to be immune to a cellular attack. In other words, making insulin-producing beta cells unrecognizable to the immune system. That’s what Elad Sintov, Ph.D., is trying to do, with a JDRF postdoctoral fellowship at Harvard University, sponsored by MilliporeSigma.